The Gordian Knot of dysbiosis, obesity and NAFLD

@article{Mehal2013TheGK,
  title={The Gordian Knot of dysbiosis, obesity and NAFLD},
  author={Wajahat Zafar Mehal},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  year={2013},
  volume={10},
  pages={637-644}
}
  • W. Mehal
  • Published 1 November 2013
  • Biology, Medicine
  • Nature Reviews Gastroenterology &Hepatology
The development of obesity and NAFLD is known to be determined by host genetics, diet and lack of exercise. In addition, the gut microbiota has been identified to influence the development of both obesity and NAFLD. Evidence for the role of the gut microbiota has been shown by preclinical studies of transfer of gut microbiota from lean and obese individuals, with the recipient developing the metabolic features of the donor. Many bidirectional interactions of the gut microbiota, including with… 

Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Several lines of evidence are presented indicating that, by increasing energy extraction in some dysbiosis conditions or small intestinal bacterial overgrowth, specific gut microbiota and/or a "low bacterial richness" may play a role in obesity, metabolic syndrome, and fatty liver.

Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?

How probiotics, prebiotics, synbiotic, fecal microbiota transfer, polyphenols, specific diets and exercise interventions have been shown to modify gut microbiota signatures, improve NAFLD outcomes is discussed and detail, when available, the different mechanisms by which these beneficial outcomes might occur is discussed.

NASH and the Cross-Talk Between the Gut and Liver

An overview of the current knowledge on the pathophysiology of the cross-talk between the gut and the liver in the pathogenesis of NAFLD and its progression to NASH is provided, and potential therapeutic means to manipulate the intestinal microbiota in order to modulate liver disease development are discussed.

Gut Microbiota: Association with NAFLD and Metabolic Disturbances

The main objective of this review is to address the pathogenic association of gut microbiota to NAFLD, and to allow the development of integrated strategies to modulate intestinal microbiota in order to treatNAFLD.

Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota

This review summarized the most recent advances in gut microbiota-mediated mechanisms, as well as Gut microbiota-targeted therapies on NAFLD.

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy

This review reviews the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies forNAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiome-targeting therapies in the future.

The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease

An in-depth review of the progression of NAFLD is provided, discussing the mechanistic modes of hepatocyte injury and the potential role for manipulation of the gut microbiome as a therapeutic strategy in the prevention and treatment ofNAFLD.

A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction.

...

References

SHOWING 1-10 OF 117 REFERENCES

The gut microbiota, obesity and insulin resistance.

Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.

The role of the gut microbiota and metabolic endotoxemia-induced inflammation in the development of obesity and liver injury is reviewed, with special reference to the intensive care unit setting.

Gut microbiota and non-alcoholic fatty liver disease: new insights.

The gut microbiota is involved in gut permeability, low-grade inflammation and immune balance, it modulates dietary choline metabolism, regulates bile acid metabolism and produces endogenous ethanol, all of which are molecular mechanisms by which the microbiota can induce NAFLD or its progression toward overt non-alcoholic steatohepatitis.

Probiotics in the Treatment of the Liver Diseases

The present review summarizes the recent studies highlighting the role of the intestinal microflora in the development of NAFLD and ALD and the potential efficacy of probiotics as a therapeutic strategy for liver diseases.

Liver repercussions of defective gut surveillance

Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Altered interactions between the gut microbiota and the host, produced by defective NLRP3 and NLRP6 inflammasome sensing, may govern the rate of progression of multiple metabolic syndrome-associated abnormalities, highlighting the central role of the microbiota in the pathogenesis of heretofore seemingly unrelated systemic auto-inflammatory and metabolic disorders.

Gut microbiota and probiotics in chronic liver diseases.

  • C. CesaroA. Tiso C. Loguercio
  • Medicine, Biology
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2011

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

  • K. Cusi
  • Medicine, Biology
    Gastroenterology
  • 2012
Treatments that rescue the liver from lipotoxicity by restoring adipose tissue insulin sensitivity or preventing activation of inflammatory pathways and oxidative stress hold promise in the treatment of NAFLD, although their long-term safety and efficacy remain to be established.

The potential role of prebiotic fibre for treatment and management of non‐alcoholic fatty liver disease and associated obesity and insulin resistance

Current knowledge about prebiotics as an emerging therapeutic target for NAFLD is summarized to summarize and future research should focus on placebo‐controlled, human, clinical trials using histological endpoints to address the effects of prebiotic fibres onNAFLD and NASH.

The gut microbiota as an environmental factor that regulates fat storage.

It is found that conventionalization of adult germ-free (GF) C57BL/6 mice with a normal microbiota harvested from the distal intestine of conventionally raised animals produces a 60% increase in body fat content and insulin resistance within 14 days despite reduced food intake.
...